OCLN and congenital rubella syndrome: Network pharmacology was employed to identify the molecular target of GA, which was subsequently validated through in vitro experiments using human nasal epithelial cells by analyzing the Syk/NF-κB pathway and downstream inflammatory cytokines.<h4>Results</h4>In CRS mice, nanozyme treatment significantly alleviated nasal mucosal inflammation, reduced inflammatory cytokine levels, and restored Occludin and ZO-1 expression, indicating epithelial barrier repair.